Governance

Governance and Operating Committee

Operating Committee

The IRDiRC Operating Committee (OpComm), composed of the chairs of all constituent and scientific committees, sets IRDiRC strategic priorities, key objectives, and policy positions, which are validated through the Consortium Assembly to ensure an equilibrated governance and public policy alignment. Task Forces and Working Groups are formed annually for a period of maximum 18 months to work on specific projects focused on international emerging research topics.

IRDiRC’s mission towards creating a strong collaborative environment is accomplished by bringing together the expertise of multi-stakeholders with the ultimate goal of advancing research in RD field, by proposing innovative approaches.

David Pearce

Chair | Consortium Assembly

Professor, Department of Pediatrics at Sanford School of Medicine at University of South Dakota, USA

Samantha Parker

Vice Chair | Consortium Assembly

Patient Advocacy and Communication Lead Rare Disease Europe, ITALFARMACO, France

Christopher McMaster

Chair | FCC

Scientific Director, Canadian Institutes for Health Research (CIHR), Canada

Stefano Benvenuti

Vice Chair | FCC

Head of Public Affairs, Telethon Foundation, Italy

Vinciane Pirard

Chair | CCC

Lead Scientific Advocacy and Insights – Global Medical Affairs Rare Diseases at SANOFI, Belgium

Adriana Huertas-Vazquez

Vice Chair | CCC

Senior Director, Global Medical Affairs at Illumina, USA

Kelly du Plessis

Chair | PACC

Member, Rare Diseases International, South Africa

Tammi Shipowick

Vice Chair | PACC

Program Director at Global Skin, Canada

Sally Ann Lynch

Chair | DSC

Consultant Clinical Geneticist, Children’s Health Ireland, Ireland

Saumya Shekhar Jamuar

Vice Chair | DSC

Medical Director, KK Women’s and Children’s Hospital, Singapore

Gareth Baynam

Chair | ISC

Medical Director at Rare Care Centre, Perth Children’s Hospital, Australia

Helen Malherbe

Vice Chair | ISC

Associate Professor, Centre for Human Metabolomics, North-West University, South Africa

Daniel O'Connor

Chair | TSC

Director, Regulatory Policy and Early Access, The Association of the British Pharmaceutical Industry (ABPI), UK

Anneliene Jonker

Vice Chair | TSC

Assistant Professor, Rare Diseases Therapeutic Innovation, University of Twente & Scientific Director, Duchenne Parent Project, The Netherlands

Violeta Stoyanova-Beninska

Chair | RSC

Senior Scientific Specialist at European Medicines Agency, Netherlands

Oxana Iliach

Vice Chair | RSC

Senior Director Regulatory Strategy, Certara, Canada

Governance Documents